BLFS - BioLife Solutions Inc Stock Price, Fair Value and News

17.19USD+0.17 (+1.00%)Market Closed

Market Summary

USD17.19+0.17

Market Closed

1.00%

BLFS Alerts

1 major insider sales recently.

BLFS Stock Price

View Fullscreen

BLFS RSI Chart

BLFS Valuation

Market Cap

778.7M

Price/Earnings (Trailing)

-11.72

Price/Sales (Trailing)

5.44

EV/EBITDA

-13.31

Price/Free Cashflow

-41.25

BLFS Price/Sales (Trailing)

BLFS Profitability

EBT Margin

-46.25%

Return on Equity

-19.67%

Return on Assets

-16.1%

Free Cashflow Yield

-2.42%

BLFS Fundamentals

BLFS Revenue

Revenue (TTM)

143.3M

Rev. Growth (Yr)

-26.04%

Rev. Growth (Qtr)

-1.79%

BLFS Earnings

Earnings (TTM)

-66.4M

Earnings Growth (Yr)

72.79%

Earnings Growth (Qtr)

54.06%

Breaking Down BLFS Revenue

Last 7 days

13.5%

Last 30 days

-8.6%

Last 90 days

0.2%

Trailing 12 Months

-5.2%

How does BLFS drawdown profile look like?

BLFS Financial Health

Current Ratio

2.86

Debt/Equity

0.05

Debt/Cashflow

-0.68

BLFS Investor Care

Shares Dilution (1Y)

2.96%

Diluted EPS (TTM)

-2.35

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	163.2M	162.2M	154.8M	143.3M
2022	138.5M	147.9M	154.8M	161.8M
2021	52.8M	74.1M	96.6M	119.2M
2020	33.8M	37.0M	41.7M	48.1M
2019	21.7M	23.2M	24.5M	27.4M
2018	12.5M	15.1M	17.4M	19.7M
2017	8.7M	9.3M	10.1M	11.0M
2016	6.8M	7.3M	7.8M	8.2M
2015	5.6M	5.9M	6.3M	6.4M
2014	9.6M	8.5M	7.6M	6.2M
2013	5.4M	6.7M	7.2M	8.2M
2012	3.0M	3.5M	4.4M	5.7M
2011	2.3M	2.4M	2.6M	2.8M
2010	0	0	0	2.1M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of BioLife Solutions Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 22, 2024	aebersold sarah	sold	-6,765	16.5	-410	chief human resources officer
Apr 18, 2024	mathew aby j.	sold	-8,941	15.31	-584	evp & chief scientific officer
Apr 18, 2024	berard todd	sold	-5,082	15.31	-332	chief marketing officer
Apr 18, 2024	foster karen a.	sold	-7,364	15.31	-481	chief quality and operations
Apr 18, 2024	wichterman troy	sold	-14,636	15.31	-956	chief financial officer
Apr 18, 2024	aebersold sarah	sold	-5,327	15.31	-348	chief human resources officer
Apr 15, 2024	berard todd	sold	-156,700	15.67	-10,000	chief marketing officer
Apr 01, 2024	aebersold sarah	sold	-70,600	17.65	-4,000	chief human resources officer
Mar 27, 2024	foster karen a.	sold	-7,106	17.99	-395	chief quality and operations
Mar 27, 2024	berard todd	sold	-9,264	17.99	-515	chief marketing officer

Which funds bought or sold BLFS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Louisiana State Employees Retirement System	added	1.15	43,730	326,480	0.01%
Apr 23, 2024	FIFTH THIRD BANCORP	unchanged	-	258	2,078	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-24.53	-33,000	206,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	45,611	303,761	-%
Apr 19, 2024	Maryland State Retirement & Pension System	unchanged	-	-10,377	195,267	-%
Apr 19, 2024	State of Alaska, Department of Revenue	added	1.31	55,000	402,000	-%
Apr 19, 2024	Mesirow Financial Investment Management, Inc.	reduced	-23.01	-77,853	381,444	1.90%
Apr 18, 2024	FARMERS & MERCHANTS INVESTMENTS INC	unchanged	-	55.00	445	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	added	161,879	2,432,500	2,433,820	-%
Apr 18, 2024	Penbrook Management LLC	reduced	-1.71	81,200	746,638	0.46%

Are Funds Buying or Selling BLFS?

Are funds buying BLFS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BLFS

No. of Funds

BLFS Alerts

1 major insider sales recently.

Unveiling BioLife Solutions Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	5.71%	2,571,608	SC 13G/A
Feb 02, 2024	goldman sachs group inc	5.5%	2,476,242	SC 13G
Jan 24, 2024	integrated core strategies (us) llc	5.3%	2,404,862	SC 13G/A
Jan 23, 2024	blackrock inc.	12.3%	5,424,116	SC 13G/A
Oct 24, 2023	casdin capital, llc	19.5%	8,707,165	SC 13D/A
Sep 26, 2023	integrated core strategies (us) llc	5.5%	2,406,913	SC 13G
Feb 09, 2023	vanguard group inc	5.77%	2,466,931	SC 13G/A
Jan 26, 2023	blackrock inc.	12.8%	5,477,126	SC 13G/A
Jan 20, 2023	blackrock inc.	12.8%	5,477,126	SC 13G/A
Jan 11, 2023	millennium management llc	1.6%	670,202	SC 13G/A

Recent SEC filings of BioLife Solutions Inc

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	8-K	Current Report
Apr 18, 2024	4	Insider Trading
Apr 18, 2024	8-K	Current Report
Apr 03, 2024	4	Insider Trading
Mar 29, 2024	4	Insider Trading

Peers (Alternatives to BioLife Solutions Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	185.5B	40.1B	-2.82%	-2.78%	32.41	4.63	-8.12%	-17.45%
BDX	67.5B	19.5B	-3.26%	-10.41%	53.77	3.46	4.02%	-22.04%
ALGN	23.6B	3.9B	-1.72%	-10.74%	52.95	6.1	3.42%	23.09%
BAX	20.8B	14.8B	-2.03%	-9.90%	7.83	1.4	2.12%	209.17%
MID-CAP
HSIC	9.4B	12.3B	0.44%	-12.46%	22.62	0.76	-2.44%	-22.68%
ATR	9.2B	3.5B	-2.07%	18.57%	32.49	2.65	4.97%	18.89%
BIO	8.1B	2.7B	-18.49%	-36.41%	-12.74	3.04	-4.68%	82.43%
XRAY	6.4B	4.0B	-5.85%	-24.53%	-47.67	1.62	1.10%	85.84%
AXNX	3.4B	366.4M	-3.04%	14.62%	-560.04	9.28	33.86%	89.83%
PDCO	2.3B	6.6B	-3.54%	-1.62%	12.12	0.36	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-13.37%	-14.88%	-1.92	0.41	7.73%	-1066.14%
ANIK	384.6M	166.7M	3.23%	-3.00%	-4.65	2.31	6.67%	-456.34%
ANGO	235.1M	324.0M	11.39%	-31.43%	-1.22	0.73	-3.19%	-337.41%
APYX	52.0M	52.3M	18.11%	-48.10%	-2.78	0.99	17.61%	19.28%
AEMD	4.0M	3.7M	-12.07%	240.00%	-0.33	1.07	5.77%	8.23%

BioLife Solutions Inc News

Latest updates

BioLife Solutions Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-1.8%	32,732,500	33,328,000	39,508,000	37,703,000	44,259,000	40,747,000	40,533,000	36,220,000	37,305,000	33,800,000	31,204,000	16,847,000	14,726,000	11,279,000	9,920,000	12,162,000	8,296,000	6,604,000	6,701,000	5,770,000	5,456,000
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,520,000	4,743,000	4,123,000	3,746,000
Costs and Expenses	-26.1%	45,888,500	62,111,000	54,788,000	51,308,000	93,530,000	52,487,000	117,096,000	44,187,000	55,770,000	44,959,000	35,759,000	17,828,000	20,135,000	12,525,000	9,876,000	11,792,000	9,057,000	7,376,000	5,954,000	5,204,000	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7,376,000	5,954,000	5,204,000	-1,803,500
S&GA Expenses	-37.5%	4,538,000	7,256,000	6,318,000	6,471,000	5,977,500	5,278,000	5,415,000	4,891,000	4,778,000	4,065,000	3,142,000	2,021,000	1,883,000	1,588,000	1,366,000	1,576,000	1,669,000	1,250,000	945,000	837,000	637,000
R&D Expenses	-18.5%	4,400,500	5,402,000	4,840,000	4,152,000	4,164,000	3,425,000	3,428,000	3,781,000	3,570,500	3,219,000	3,045,000	1,987,000	1,855,000	1,725,000	1,477,000	1,663,000	1,086,000	1,032,000	691,000	359,000	315,000
EBITDA Margin	33.5%	-0.40	-0.60	-0.46	-0.87	-0.85	-0.69	-0.68	-0.22	-0.20	-0.14	-0.14	-0.42	0.02	-	-	-	-	-	-	-	-
Interest Expenses	16.1%	533,000	459,000	438,000	497,000	356,000	109,000	30,000	91,000	452,000	-	-	-	-4,000	3,000	-	1,000	-5,000	1,000	1,000	3,000	1,500
Income Taxes	-137.4%	-43,000	115,000	5,000	92,000	-85,000	-599,000	-3,739,000	-599,000	-2,578,000	-4,988,000	-12,552,000	-	-3,264,000	-	-	-	-1,541,000	-	-	-	-
Earnings Before Taxes	53.7%	-13,425,000	-29,017,000	-10,194,000	-13,622,000	-49,274,000	-10,916,000	-76,617,000	-8,020,000	-18,323,000	-4,909,000	-4,676,000	-1,118,000	-6,076,000	-1,133,000	-16,380,000	22,308,000	1,442,000	10,269,000	4,252,000	-19,161,000	-27,378,000
EBT Margin	29.9%	-0.46	-0.66	-0.52	-0.92	-0.90	-0.74	-0.73	-0.26	-0.24	-0.17	-0.18	-0.47	-0.03	-	-	-	-	-	-	-	-
Net Income	54.1%	-13,382,000	-29,132,000	-10,199,000	-13,714,000	-49,189,000	-10,317,000	-72,878,000	-7,421,000	-15,745,000	79,000	7,876,000	-1,118,000	-2,812,000	-1,133,000	-16,380,000	22,308,000	2,983,000	10,269,000	4,252,000	-19,161,000	20,933,000
Net Income Margin	29.8%	-0.46	-0.66	-0.51	-0.89	-0.86	-0.69	-0.65	-0.11	-0.07	0.04	0.04	-0.41	0.04	-	-	-	-	-	-	-	-
Free Cashflow	122.6%	1,330,000	-5,875,000	-8,327,000	-6,007,000	3,409,000	-950,000	-11,952,000	-9,380,000	-2,340,000	-329,000	-10,409,000	100,000	666,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	0.4%	413	411	433	446	450	488	471	544	554	559	521	240	235	196	114	95.00	93.00	84.00	51.00	48.00	45.00
Current Assets	3.2%	121	117	120	133	138	136	118	119	126	131	127	117	115	128	46.00	26.00	24.00	32.00	29.00	39.00	38.00
Cash Equivalents	84.1%	35.00	19.00	21.00	19.00	19.00	27.00	24.00	59.00	70.00	75.00	76.00	89.00	90.00	94.00	30.00	6.00	6.00	21.00	20.00	32.00	31.00
Inventory	0.2%	43.00	43.00	39.00	41.00	35.00	34.00	33.00	30.00	28.00	30.00	26.00	12.00	12.00	11.00	11.00	11.00	11.00	6.00	5.00	4.00	4.00
Net PPE	0.4%	21.00	21.00	26.00	26.00	24.00	22.00	19.00	18.00	18.00	17.00	16.00	11.00	10.00	5.00	5.00	5.00	6.00	2.00	1.00	1.00	1.00
Goodwill	0%	225	225	225	225	225	225	225	225	58.00	224	196	58.00	58.00	25.00	34.00	34.00	34.00	28.00	10.00	10.00	-
Liabilities	-5.2%	75.00	79.00	81.00	88.00	86.00	83.00	61.00	68.00	76.00	70.00	69.00	31.00	30.00	9.00	8.00	27.00	49.00	49.00	49.00	52.00	31.00
Current Liabilities	-1.0%	42.00	43.00	40.00	47.00	45.00	40.00	36.00	38.00	43.00	36.00	31.00	16.00	16.00	8.00	7.00	25.00	8.00	5.00	3.00	3.00	2.00
Long Term Debt	-12.5%	18.00	21.00	24.00	24.00	24.00	24.00	6.00	6.00	6.00	6.00	5.00	-	1.00	-	-	-	-	-	-	-	-
LT Debt, Current	35.7%	7.00	5.00	2.00	1.00	2.00	2.00	1.00	1.00	1.00	2.00	3.00	-	1.00	-	-	-	-	-	-	-	-
LT Debt, Non Current	-12.5%	18.00	21.00	24.00	24.00	24.00	24.00	6.00	6.00	6.00	6.00	5.00	-	1.00	-	-	-	-	-	-	-	-
Shareholder's Equity	1.7%	338	332	352	358	364	405	410	476	478	489	452	209	204	187	106	68.00	43.00	35.00	2.00	44.00	15.00
Retained Earnings	-4.5%	-313	-299	-270	-260	-246	-197	-187	-114	-107	-90.55	-90.63	-98.50	-97.38	-95.26	-94.12	-77.74	100	-103	-113	-117	-98.39
Additional Paid-In Capital	3.0%	651	633	623	619	612	604	598	591	585	580	543	307	303	282	200	145	143	138	115	114	113
Accumulated Depreciation	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.00	2.00	2.00	2.00	2.00
Shares Outstanding	3.0%	45.00	44.00	43.00	43.00	43.00	42.00	42.00	42.00	39.00	37.00	38.00	33.00	27.00	-	-	-	-	-	-	-	-
Float	-	-	-	774	-	-	-	473	-	-	-	1,433	-	-	-	263	-	-	-	230	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	152.8%	2,311	-4,379	-7,718	-2,712	7,857	1,496	-9,917	-7,924	-774	2,083	-7,722	1,820	2,257	-502	4,203	687	-1,003	1,137	-67.00	1,146	585
Share Based Compensation	-8.6%	8,333	9,117	6,857	7,363	7,663	6,299	5,973	5,399	5,065	4,867	2,519	1,505	2,163	1,560	1,145	1,113	864	830	818	531	388
Cashflow From Investing	138.1%	3,957	1,662	9,292	2,926	-14,894	-15,883	-25,070	-2,270	-2,542	-2,007	-4,216	-4,427	-22,057	-975	-456	-1,227	-14,021	-292	-12,549	-156	-161
Cashflow From Financing	1518.6%	9,841	608	704	-562	-625	17,411	-289	-181	-2,105	-1,058	-831	1,216	1,272	80,582	19,732	492	267	743	409	177	-2,148

BLFS Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Total product, service, and rental revenue	$ 143,271	$ 161,759	$ 119,156
Costs and operating expenses:
General and administrative	55,725	47,670	33,668
Sales and marketing	24,583	21,570	14,006
Research and development	18,796	14,798	11,821
Asset impairment charges	15,485	110,364	0
Intangible asset amortization	5,181	9,697	8,202
Acquisition costs	0	18	1,636
Change in fair value of contingent consideration	(2,193)	(4,754)	2,875
Total operating expenses	214,096	307,300	154,316
Operating loss	(70,825)	(145,541)	(35,160)
Other income:
Change in fair value of warrant liability	0	0	(121)
Change in fair value of investments	0	697	0
Interest expense, net	(1,812)	(687)	(485)
Other income	1,264	704	289
Gain on settlement of Global Cooling escrow	5,115	0	0
Gain on acquisition of Sexton Biotechnologies, Inc.	0	0	6,451
Total other income, net	4,567	714	6,134
Loss before income tax (expense) benefit	(66,258)	(144,827)	(29,026)
Income tax (expense) benefit	(169)	5,022	20,118
Net loss	(66,427)	(139,805)	(8,908)
Net loss attributable to common shareholders:
Net loss attributable to common shareholders, basic	(66,427)	(139,805)	(8,908)
Net loss attributable to common shareholders, diluted	$ (66,427)	$ (139,805)	$ (8,908)
Net loss per share attributable to common shareholders:
Basic (in dollars per share)	$ (1.52)	$ (3.29)	$ (0.23)
Diluted (in dollars per share)	$ (1.52)	$ (3.29)	$ (0.23)
Weighted average shares used to compute loss per share attributable to common shareholders:
Basic (in shares)	43,719,185	42,481,027	38,503,944
Diluted (in shares)	43,719,185	42,481,027	38,503,944
Product revenue
Total product, service, and rental revenue	$ 117,695	$ 136,000	$ 101,913
Costs and operating expenses:
Cost of revenue	75,751	88,519	69,676
Service revenue
Total product, service, and rental revenue	17,551	15,308	9,817
Costs and operating expenses:
Cost of revenue	15,586	12,360	5,381
Rental revenue
Total product, service, and rental revenue	8,025	10,451	7,426
Costs and operating expenses:
Cost of revenue	$ 5,182	$ 7,058	$ 7,051

BLFS Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 35,407	$ 19,442
Restricted cash	31	31
Available-for-sale securities, current portion	16,288	43,260
Accounts receivable, trade, net of allowance for credit losses of $1,710 and $739 as of December 31, 2023 and December 31, 2022, respectively	18,657	33,936
Inventories	43,456	34,904
Prepaid expenses and other current assets	6,765	6,879
Total current assets	120,604	138,452
Assets held for rent, net	7,713	9,064
Property and equipment, net	21,077	23,638
Operating lease right-of-use assets, net	11,446	15,292
Financing lease right-of-use assets, net	94	272
Long-term deposits and other assets	273	281
Available-for-sale securities, long term	548	1,332
Equity Investments	5,069	5,069
Intangible assets, net	21,149	32,088
Goodwill	224,741	224,741
Total assets	412,714	450,229
Current liabilities:
Accounts payable	6,940	15,367
Accrued expenses and other current liabilities	11,932	9,782
Sales taxes payable	5,442	4,151
Warranty liability	7,858	8,312
Lease liabilities, operating, current portion	2,797	2,860
Lease liabilities, financing, current portion	376	158
Debt, current portion	6,833	1,814
Contingent consideration, current portion	0	2,138
Total current liabilities	42,178	44,582
Contingent consideration, long-term	0	2,318
Lease liabilities, operating, long-term	13,205	14,962
Lease liabilities, financing, long-term	1,169	126
Debt, long-term	18,311	23,793
Deferred tax liabilities	188	250
Other long-term liabilities	0	10
Total liabilities	75,051	86,041
Commitments and contingencies (Note 12)
Shareholders’ equity:
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of December 31, 2023 and December 31, 2022	0	0
Common stock, $0.001 par value; 150,000,000 shares authorized, 45,167,225 and 42,832,231 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	45	43
Additional paid-in capital	651,305	611,739
Accumulated other comprehensive loss, net of taxes	(345)	(679)
Accumulated deficit	(313,342)	(246,915)
Total shareholders’ equity	337,663	364,188
Total liabilities and shareholders’ equity	$ 412,714	$ 450,229

About BioLife Solutions Inc

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; ultra-low temperature mechanical freezers; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.

CEO	Mr. Michael P. Rice
WEBSITE	biolifesolutions.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	466

BioLife Solutions Inc Frequently Asked Questions

What is the ticker symbol for BioLife Solutions Inc? What does BLFS stand for in stocks?

BLFS is the stock ticker symbol of BioLife Solutions Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BioLife Solutions Inc (BLFS)?

As of Wed Apr 24 2024, market cap of BioLife Solutions Inc is 778.71 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BLFS stock?

You can check BLFS's fair value in chart for subscribers.

What is the fair value of BLFS stock?

You can check BLFS's fair value in chart for subscribers. The fair value of BioLife Solutions Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of BioLife Solutions Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BLFS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is BioLife Solutions Inc a good stock to buy?

The fair value guage provides a quick view whether BLFS is over valued or under valued. Whether BioLife Solutions Inc is cheap or expensive depends on the assumptions which impact BioLife Solutions Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BLFS.

What is BioLife Solutions Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, BLFS's PE ratio (Price to Earnings) is -11.72 and Price to Sales (PS) ratio is 5.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BLFS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on BioLife Solutions Inc's stock?

In the past 10 years, BioLife Solutions Inc has provided 0.179 (multiply by 100 for percentage) rate of return.